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Introduction 
Purines are heterocyclic aromatic organic compounds consisting of two 5 and 6 
membered fused rings containing nitrogen. They are present in numerous compounds, 
including natural products, with potent biological activity. Purine analogs are used for 
the treatment of acute leukemias. Thiopurine derivatives are effective antiviral 
(acyclovir, ganciclovir) or antitumor agents such as vidarabine, among other clinical 
uses [1]. 
 Over the years, the purine nucleus has become one important pharmacophoric 
group. It is capable of interfering in the synthesis and function of enzymes and nucleic 
acids. It is also frequently used in the development of protein kinase inhibitors [2]. 
 Our research group has developed new routes to produce purine libraries. One 
of such routes is the one-pot synthesis [3] to obtain 6-, 8-, and 9-substituted purines from 
4-alkylamino-5-amino-6-chloropirimidines, alcohols and N,N-dimethylamides. We also 
presented a new approach [4], to obtain trisubstituted purines. We were able to prepare a 
library of polysubstituted purines. Some compounds from this library were found to be 
specific inhibitors of the Death-Associated Protein Kinase-1 [5] (DAPK1). The leading 
compounds of this library are potent inducers of apoptosis in tumor lymphocytes and 
also reduce viability of trypanosomes [4, 6]. 
 We herein report the unambiguous assignment of 1H and 13C of a subset of 
these new purine derivatives. Assignments were carried out in compounds 3k and 3n 
which have, as substituents, phenyl and benzyl at positions 6 and 8, respectively. We 
also characterize compound 3o, which has benzyl, phenyl and phenethyl substituents at 
positions 6, 8 and 9, respectively. We therefore provide better knowledge of the 
molecular structure of our compounds, while obtaining further insight for future 
structure-activity studies and for improving the structural determination of other purine 
derivatives. 
 Experimental 
 
Synthesis 
Purines were prepared as described elsewhere [4], [5] 
 
Scheme 1 shows the previously reported synthetic pathway to obtain the novel 
family of purine derivatives 3a-o. Trisubstituted purines at positions 6, 8 and 9 were 
prepared starting from 6-chloro-4,5-diaminopyrimidine, alcohols and N, N-
dimethylamides in basic conditions without metal catalysis. Depending on the size of 
the R1 substituent of the amides (Scheme 1), two different synthetic routes may occur. 
Route A results in purine analogs whose C8 substituents are derived from the amide, 
whereas Route B gives rise to purines with C8 substituents coming from the alcohol. 
Route A proceeds via in situ generation of N-alkylimidate species, which are created by 
reaction between amides and alkoxides leading to purine derivatives with either H or 
methyl in C8 when using N,N-dimethylformamide or N,N-dimethylacetamide, 
respectively. When steric hindrance of amides increases, such as in the cases of N,N-
dimethylbenzamide or N,N-dimethylpropionamide, Route A is then impeded and a 
metal-free tandem alcohol oxidation/annulation reaction occurs giving rise to Route B 
products. Therefore, competition between N-alkylimidate formation and metal-free 
oxidative coupling of primary alkoxides and diaminopyrimidines with Schiff base 
formation and subsequent annulation can be controlled. In both routes SNAr of the 
chloro atom at C6 by alkoxides takes place and, along with the R3 group of exocyclic 
nitrogen located at C4 of the starting pyrimidine, increases structural diversity of these 
one-pot synthesis. 
 Scheme 1 may be inserted about here. 
 
This synthetic platform, therefore, allows the creation of a diversity of purine 
analogues in a parallel and straightforward fashion using a variety of amides and 
alcohols with different pyrimidines under the same reaction conditions. Scheme 2 
shows the set of 15 purines presented here, which were obtained through either Route A 
or B. 
 
Scheme 2 may be inserted about here. 
 
NMR Techniques 
1H and 13C NMR data (chemical shifts multiplicity and coupling constants) for 
compounds 3a-n are shown in Tables below. Unambiguous assignments for all NMR 
signals were accomplished by combined analysis of 1H, 13C, 90º DEPT, HSQC and 
HMBC, COSY and TOCSY NMR experiments. 
¹H Nuclear magnetic resonance spectra were recorded on a Varian Inova Unity 
(300 MHz), Varian Direct Drive (400 MHz) and/or Varian Direct Drive (500 MHz). 
Chemical shifts (δ) are referenced to the residual solvent peak: CDCl3, δ 7.26 (1H), δ 
77.16 (13C). Spin multiplicities are given as s (singlet), bs (broad singlet), d (doublet), 
dd (double doublet), ddd (double double doublet), t (triplet), dt (double triplet), pt 
(pseudotriplet), q (quadruplet) and m (multiplet). Coupling constants (J) are given in 
Hz. 13C NMR were recorded on a Varian Direct Drive (400 MHz) and Varian Direct 
Drive (500 MHz). DEPT experiments were carried out using the standard pulse 
sequence [7].  The HMBC, HSQC, H2BC, COSY, TOCSY DEPT spectra were 
measured with a pulse sequence gc2hmbc, gc2hsqcse, gc2h2bc, gCOSY, gTOCSY 
gDEPT respectively (Standard sequence Agilent Vnmrj 4.2A software) [8]. 
 
 
Results and discussion 
 
Analysis of 1H and 13C-NMR spectra 
To facilitate the analysis of all purines, NMR data are presented in tables. 
Substituent at 6, 8 and 9 positions of the purine ring are named as R1, R2 and R3 
respectively. Table 1 and 2 show 1H and 13C-NMR chemical shifts (δ) for compounds 
(3a-o). 
Table 3 shows the family of compounds derived from purine as well as the 
number scheme of the compounds used. 
Table 3 may be inserted here. 
In particular, we focused the analysis in protons belonging to phenyl, benzyl and 
phenethyl aromatic rings within a same molecule, as for compounds 3o, 3k and 3n.  
TOCSY method was used to identify unequivocally these aromatic protons of our 
compounds. Purine 3o was firstly analyzed. Irradiation frequency of δ 7.55 presents an 
associated spin system which corresponds with aromatic protons of the R1 benzyl 
substituent located at C6 of the purine ring. In the case of irradiation frequency of δ 
7.50, the associated spin system corresponds to protons of the aromatic ring appearing 
at position 8 of the purine ring (R2), a phenyl substituent. Finally, irradiation frequency 
of δ 7.19 present an associated spin system which corresponds to protons of the R3 
substituent located at C9 of the purine ring, a phenethyl group. 
Once chemical shifts of the protons of the three types of aromatic rings at purine 
substituents were identified, coupling techniques to identify C-H and H-H interactions 
at short and long distances (HSQC, HMBC, COSY, TOCSY and H2BC) were used to 
unequivocally assign protons of the three different aromatic rings at 6, 8 and 9 positions 
of compound 3o as shown in Table 1. Therefore, by means of TOCSY studies we 
unequivocally assigned the protons of the aromatic rings which appear in positions 6, 8 
and 9 of the purine ring (Table 1). A similar procedure was carried out to assign the 
aromatic protons of compounds 3k and 3n. 
 
Table 2 and 4 shows the 13C-NMR data. Similar to our 1H-NMR analysis, unambiguous 
assignment of 13C chemical shifts was performed for the three aromatic rings, phenyl, 
benzyl and phenethyl substituents at positions 6, 8 and 9 of purine 3o, as well as for 
carbons of the aromatic substituents, benzyl and phenyl, located at C6 and C8 of purines 
3k and 3n.  
For compound 3o, quaternary carbons were assigned using 90º DEPT and 13C-
NMR spectra. Chemical shifts at δ 160.32, 153.96, 153.34, 137.27, 136.40, 129.66 and 
121.40 correspond to C4, C5, C6 and C8 of the purine ring of phenyl, benzyl and 
phenethyl rings, located at C6, C8 and N9. These assignments were confirmed by 
analysis of HSQC spectra. HMBC spectrum indicated that the methylene protons of the 
benzyl substituent located at C6 of the purine ring showed coupling with the quaternary 
carbon appearing at δ 160.32, corresponding to C6. The same methylene protons were 
coupled to the quaternary carbon of the aromatic ring substituent at C6. Carbon C1’ was 
at δ 136.40. The proton at C2 of the purine ring (δ 8.58) is coupled long-distance with 
C6 and with C4 at δ 153.96. The methylene protons of the phenethyl group (δ 5.71), 
substituent at C9 are coupled to C1’ (δ 137.27) and with C4. The quaternary carbon at δ 
121.40 was assigned to C5, since was not coupled with any hydrogen. The quaternary 
carbon δ 153.34 wa assigned to C8, since in the HMBC spectrum it showed coupling to 
the aromatic protons of the substituent phenyl ring. The signal of the quaternary carbon 
at δ 129.66 was assigned to C1 of the phenyl group of the substituent at C8 of the purine 
ring. 
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Captions to scheme and figures: 
 
Scheme 1.- Proposed mechanisms of action for routes A and B. 
 
Scheme 2.- Synthetic routes to generate purine types "A" or "B" and set of 15 purines 
prepared through either Route A or B. 
 
Table 1.- Family of compounds derivative of 6,8,9 poly-substituted purine. 
Table 1 1H-NMR chemical shifts () and coupling constants (J, Hz) of purine derivatives (3a-o) 
Compound H-2 H-8 R1 R2 R3 
3a 
 
8.48 (s) 7.96 (s) 
4.63 (q, 7), 
1.47 (t, 7) 
- 
4.85 (m), 
1.59 (d, 7) 
3b 
 
8.42 (s) - 
4.62 (q, 7), 
1.49 (t, 7) 
2.64 (s) 
4.74 (m), 
1.68 (d, 6.5) 
3c 
 
8.54 (s) 7.99 (s) 
5.68 (s), 
7.54 (H2´-6´, d, 7.5), 
7.36 (H3´-5´, dd, 7.5, 1.5), 
7.31 (H4´, dd,  7.5, 1.5) 
- 
4.89 (m), 
1.63 (d, 7) 
3d 
 
8.46 (s) - 
5.64 (s), 
7.53 (H2´-6´, d, 7.5), 
7.34 (H3´-5´, dd, 7.5, 2), 
7.30 (H4´, dd, 7.5, 2) 
2.64 (s) 
4.74 (m), 
1.68 (d, 7) 
3e 
 
8.51 (s) 7.95 (s) 
5.67 (m), 
1.62 (d, 6.90) 
- 
4.88 (m), 
1.47 (d, 6) 
3f 
 
8.55 (s) 7.88(s) 
4.66 (q, 7), 
1.51 (t, 7) 
- 
5.40 (s), 
7.35- 7.30 (m), 
7.27 (dd, 8) 
3g 
 
8.50 (s) - 
4.65 (q, 7), 
1.51 (t, 7) 
2.51 (s) 
5.40 (s), 
7.32 (H4´, dd, 6, 2), 
7.28 (H3´-5´, dd, 6, 2), 
7.14 (H2´-6´,dd, 6, 2) 
 
 
 
 
3h 
 
 
8.58 (s) 7.89 (s) 
5.69 (s), 
7.54 (d, 7.5), 
7.38-7.34 (m) 
- 
5.41 (s), 
7.34-7.30 (m), 
7.26 (dd, 8) 
Compound H-2 H-8 R1 R2 R3 
3i 
 
8.50 (s) 7.98 (s) 
4.65 (q, 7.2), 
1.51 (t, 7.2) 
- 1.81 (s) 
3j 
 
8.52 (s) 7.50 (s) 
4.64 (q, 7.21), 
1.49 (t, 7.21) 
- 
7.25-7.17 (m), 
7.02 (dd, 8.41), 
4.46 (t, 7.21), 
3.16 (t, 7.21) 
3k 
 
8.54 (s) - 
5.69 (s), 
7.66 (m), 
7.37-7.29 (m) 
7.57-7.50 (m) 
4.76 (m), 
1.73 (d, 6.90) 
3l 
 
8.53 (s) 7.98 (s) 4.18 (s) - 
4.89 (m), 
1.62 (d, 6.5) 
3m 
 
8.43 (s) - 
4.52 (t, 7.20), 
1.26 (m), 
1.05 (t, 7.50) 
2.94 (q ,7.2), 
1.43 (t, 7.2) 
4.69 (m), 
1.70 (d, 6.90) 
3n 
 
8.55 (s) - 
5.65 (s), 
7.54 (d, 7.5), 
7.35-7.27 (m) 
7.46 (d, 7.5), 
7.45-7.38 (m) 
1.66 (s) 
  
 
 
 
 
 
 
 
 
3o 
 
8.58 (s) - 
5.71 (s), 
7.55 (d, 5.2), 
7.37-7.31 (m) 
7.48 (d, 4.4), 
7.45-7.43 (m) 
7.25-7.17 (m), 
6.91 (dd, 2.4), 
4.56 (t, 4.8), 
3.10 (t, 4.8) 
Table 2 13C-NMR chemical shifts () of purine derivatives (3a-o) 
Compound C2 C4 C5 C6 C8 R1 R2 R3 
3a 
 
151.8 152.0 122.0 160.9 139.7 
14.6 (CH3), 
63.1 (CH2) 
- 
47.5 (CH), 
22.7 (CH3) 
3b 
 
150.7 150.6 120.9 159.9 133.2 
14.7 (CH3), 
62.8 (CH2) 
15.4 
48.5 (CH), 
21.4 (CH3) 
3c 
 
151.8 152.1 122.0 160.7 139.9 
CH2 (68.5), 
C-1´ph (136.4), 
C-2´,6´ph (128.6), 
C-3´,5´ph (128.5), 
C-4´ph(128.2) 
- 
47,6 (CH), 
22,8 (CH3) 
3d 
 
150.5 150.9 120.9 159.6 140.0 
CH2 (68.23), 
C-1´ph (136.59), 
C-2´,6´ph (128.60), 
C-3´,5´ph (128.52), 
C-4´ph(128.15) 
15.4 
48.5 (CH), 
21.4 (CH3) 
3e 
 
152.0 150.2 122.2 160.8 139.5 
70.3 (CH), 
22.8 (CH3) 
- 
47.5 (CH), 
22.2 (CH3) 
3f 
 
152.5 152.3 121.5 161.1 142.0 
14.7 (CH3), 
63.3 (CH2) 
- 
CH2 (47.6), 
C-1´ph (135.5), 
C-2´,6´ph (129.2), 
C-3´,5´ph (127.9), 
C-4´ph(128.6) 
3g 
151.7 151.6 120.5 160.0 153.7 
14.5 (CH3), 
63.1 (CH2) 
14.7 
CH2 (46.2), 
C-1´ph (135.7), 
C-2´,6´ph (129.1), 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C-3´,5´ph (127.1), 
C-4´ph(128.3) 
3h 
 
 
152.4 152.5 121.6 160.8 142.2 
CH2 (68.6), 
C-1´ph (136.3), 
C-2´,6´ph (128.6), 
C-3´,5´ph (128.5), 
C-4´ph(128.3) 
- 
CH2 (47.6), 
C-1´ph (135.4), 
C-2´,6´ph (129.3), 
C-3´,5´ph (127.9), 
C-4´ph(128.7) 
Compound C2 C4 C5 C6 C8 R1 R2 R3 
3i 
 
151.1 152.4 123.1 161.1 139.8 
14.7 (CH3), 
63.0 (CH2) 
- 
57.7 (C4º), 
29.2 (CH3) 
3j 
 
152.2 152.0 121.6 160.9 142.1 
14.6 (CH3), 
63.2 (CH2) 
- 
N-CH2(45.7) 
CH2(36.3), 
C-1´ph (137.3), 
C-2´,6´ph (128.9), 
C-3´,5´ph (128.8), 
C-4´ph (127.2) 
3k 
 
150.9 153.7 122.0 160.4 153.0 
CH2 (68.3), 
C-1´ph (136.6), 
C-2´,6´ph (128.7), 
C-3´,5´ph (128.5), 
C-4´ph(128.2) 
C-1´ph (135.5), 
C-2´,6´ph (129.7), 
C-3´,5´ph (128.9), 
C-4´ph(130.3) 
49.9 (CH), 
21.4 (CH3) 
3l 
 
151.9 148.8 122.0 161.2 139.9 54.3 - 
47.6 (CH), 
22.8 (CH3) 
3m 
 
150.6 150.2 133.9 160.2 155.2 
OCH2(68.6) 
CH2 (22.4) 
CH3(10.5) 
12.4 (CH3), 
22.1 (CH2) 
48.5 (CH), 
21.4 (CH3) 
3n 
 
150.3 154.4 121.7 160.5 153.3 
CH2 (68.3), 
C-1´ph (136.5), 
C-2´,6´ph (128.8), 
C-3´,5´ph (128.5), 
C-4´ph(128.18) 
C-1´ph (134.9), 
C-2´,6´ph (130.0), 
C-3´,5´ph (128.0), 
C-4´ph(129.6) 
60.9 (C4º), 
31.0 (CH3) 
3o 
151.7 154.0 121.4 160.3 153.3 
CH2 (68.5), 
C-1´ph (136.4), 
C-1´ph (129.7), 
C-2´,6´ph (129.3), 
N-CH2(45.6) 
CH2(35.7), 
  
 
Table 3 Summary of 13C-NMR chemical shifts () of purine derivatives (3a-o) 
Compound C2 C4 C5 C6 C8 
3i-o 151.9 - 152.2 148.8 - 154.4 121.4 - 133.9 160.2 - 161.2 139.8 - 155.2 
 
 
 
 
C-2´,6´ph (128.6), 
C-3´,5´ph (128.5), 
C-4´ph(128.2) 
C-3´,5´ph (129.8), 
C-4´ph(130.3) 
C-1´ph (137.2), 
C-2´,6´ph (128.8), 
C-3´,5´ph (128.8), 
C-4´ph (127.0) 
